The FDA determined the tirzepatide shortage resolved in late 2024 and the semaglutide shortage resolved in February 2025, and it set enforcement deadlines through 2025 for compounders to wind down shortage-based production
Because nausea, vomiting, constipation, and other digestive effects can occur, meal size and food choices may need to be adjusted with professional guidance
Its generally well-tolerated when prescribed and monitored by a qualified medical professional
Extrapolating from semaglutide and tirzepatide data is reasonable given shared molecular characteristics (large protein-based structures, poor oral bioavailability), but it is not the same as having direct evidence
If you have nonalcoholic fatty liver disease (NAFLD) , you're facing a frustrating catch-22
At TrimRx, we often emphasize the importance of electrolyte balance